A 50-year-old Hong Kong woman who purchased a GLP-1 weight-loss injection online and self-administered it for three months dismissed persistent vomiting as a mere side effect. When she collapsed and was rushed to the emergency department, doctors discovered she was suffering from gastric and gallbladder adenocarcinoma that had already spread to multiple organs. The real culprit behind her relentless nausea was not the so-called “slimming shot,” but cancerous tumors blocking the exit of her stomach.
The Case: Misleading Symptoms
The woman, who stood 160 cm tall and weighed 60 kg—giving her a BMI of 23.4—had no underlying chronic conditions. Beginning in January, she injected 2.5 mg of an unregulated GLP-1 receptor agonist each week, purchased without a prescription. After three months, her weight had not dropped, but she experienced mild vomiting. Rather than seeking medical evaluation, she escalated her dose to 3.75 mg in late April.
Following her final injection, she developed severe, unrelenting nausea, vomiting, and appetite loss. Although she visited multiple clinics and even the emergency room, she never disclosed her self-medication. Medical staff repeatedly attributed her symptoms to acute gastroenteritis or drug side effects.
In early June, she lost consciousness briefly and was taken to Chi Mei Hospital. Tests revealed dangerously low sodium and potassium levels, as well as an abnormal heart rhythm. Hospitalization did not stop her vomiting. Imaging and biopsies confirmed gastric outlet obstruction caused by malignant tumors in her stomach and gallbladder. Cancer cells had metastasised to her liver, adrenal glands, lymph nodes, and lungs.
Doctor’s Warning: Who Should Use Slimming Shots?
Dr. Huang Wei-fu, an endocrinologist at Chi Mei Hospital, stressed that this patient never met the criteria for obesity pharmacotherapy. Approved weight-loss medications like semaglutide and tirzepatide are indicated only for individuals with a BMI of 30 or above, or those with a BMI of 27 or higher who also suffer from weight-related conditions such as hypertension or diabetes. At BMI 23.4, the woman fell into the healthy-weight range and had no medical need for these drugs.
GLP-1 receptor agonists work by mimicking natural hormones that regulate appetite and blood sugar. Large clinical trials have shown significant weight loss—typically 5% to 15% of body weight—when prescribed to appropriate patients, along with improvements in metabolic and cardiovascular health. However, Dr. Huang emphasised that “thinner is not always healthier,” and that self-medication or dose escalation carries serious risks.
The Critical Red Flag: Persistent Vomiting
One of the most alarming aspects of this case is that the woman’s vomiting continued to worsen even after she stopped the injections for nearly a month. “When symptoms persist or intensify despite stopping the drug, they should never be dismissed as side effects,” Dr. Huang warned.
GLP-1 drugs commonly cause gastrointestinal discomfort—nausea, diarrhoea, vomiting—but these effects typically subside within days to weeks of discontinuation. Persistent vomiting may indicate a separate underlying disease. Because the drug itself can delay gastric emptying, it may mask more serious conditions like cancer-caused obstruction.
Dr. Huang urged anyone using these medications to inform their doctors and pharmacists about every drug they take, including those bought online. Emergency visits, hospital admissions, and surgical procedures require full disclosure to avoid misdiagnosis.
Key Takeaways for Safe Weight Management
Weight-loss injections are not a shortcut. Dr. Huang cautioned that stopping such medications often leads to rebound appetite and weight regain. Moreover, rapid weight loss frequently involves loss of lean muscle mass—especially when calorie intake is severely reduced without adequate protein or resistance exercise. Middle-aged and older adults are particularly vulnerable to sarcopenia.
The doctor outlined three simple rules for the public:
- Do not buy slimming shots from unregulated online sources or social media platforms.
- Do not hide your medication history from healthcare professionals, including emergency staff and surgeons.
- Do not tough it out if expected results do not appear or side effects persist beyond a reasonable period. Return to your doctor rather than increasing your own dose.
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should avoid GLP-1 agonists entirely. Those with a history of pancreatitis require careful assessment. Women planning pregnancy must discuss discontinuation timelines with their physician.
The Bigger Picture: When Weight Loss Becomes a Health Risk
This tragic case underscores that rapid weight loss is not synonymous with safe weight management. The patient’s decision to chase a “quick fix” without medical supervision delayed the diagnosis of advanced cancer by months, likely costing her the chance for earlier intervention.
For anyone considering obesity pharmacotherapy, the path forward must include a comprehensive plan—diet, exercise, sleep optimisation, and long-term lifestyle changes—supervised by a qualified doctor. The three no’s offered by Dr. Huang provide a practical framework: never buy blindly, never hide your medication, and never ignore persistent warning signs. Symptoms like chronic vomiting, severe abdominal pain, difficulty eating, or altered consciousness demand immediate investigation—they may be the only clue to a hidden, life-threatening illness.